REG - Kanabo Group PLC - Resignation of Director

KanaboAnnouncement

24/03/2025 11:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250324:nRSX8857Ba&default-theme=true

RNS Number : 8857B  Kanabo Group PLC  24 March 2025

Kanabo Group PLC

("Kanabo" or the "Company")

 
Resignation of Director

London, UK - March 24, 2025 - Kanabo Group PLC, a leader in digital health
services and specialised medicines (including medicinal cannabis), announces
that Ian Mattioli, Non-Executive Director of the Company, has resigned with
immediate effect.

Due to health and personal reasons, Ian will spend more time committed to his
other business interests and the Board takes the opportunity to thank Ian for
his commitment to the Company during his tenure.

 

Enquiries:

 

 Kanabo Group plc                                           +44 (0)20 7469 0930

 Avihu Tamir, Chief Executive Officer

 Odelia Vazana, Chief Financial Officer

 Peterhouse Capital Limited (Financial Adviser and Broker)  +44 (0)20 7469 0930

   Guy Miller / Lucy Williams / Charles Goodfellow

About Kanabo Group plc (LSE: KNB) Kanabo Group plc is a digital health company
committed to improving patient care through its specialised technology
platform and treatments, including medicinal cannabis.

Kanabo's NHS-approved telehealth platform, The GP Service, provides video
consultations, online prescriptions, and comprehensive primary care. Treat It,
the Company's specialised clinic, extends these services to chronic pain
management and mental health indications, offering patients access to
secondary care.

With two complementary business divisions, Kanabo delivers end-to-end digital
health solutions, from telehealth consultations and prescriptions to tailored
treatments. Its partially owned subsidiary, Kanabo Agritec Ltd, offers
cultivation consultancy, enabling reliable access to high-quality raw
materials for Kanabo's product range.

Kanabo Group plc remains focused on delivering high-quality medical solutions
that make healthcare more accessible for patients across the UK and beyond.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAFDLAEESEFA